TEMPORARILY_NOT_AVAILABLE

Treating Amyotrophic Lateral Sclerosis (ALS) With R(+) Pramipexole Dihydrochloride Monohydrate at 60 mg/Day

Open Label Extension for Treating ALS With R(+) Pramipexole at 60 Milligrams Per Day

NCT00596115•Bennett, James P., Jr., M.D., Ph.D.

Summary

R(+) pramipexole dihydrochloride monohydrate \[R(+)PPX\], an experimental neuroprotective drug, is provided in this open label extension study to ALS patients who have participated in earlier clinical protocols.

Eligibility

Age

30 - 80 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Definite diagnosis of ALS

Exclusion Criteria

•No prior participation in R(+)PPX clinical studies

Key Dates

Last Updated

July 25, 2012

Conditions

Amyotrophic Lateral Sclerosis

Interventions

R(+) pramipexole dihydrochloride monohydrate

DRUG

Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS

NCT07322003

Amyotrophic Lateral Sclerosis

View study

RECRUITING

Intermuscular Coherence as a Biomarker for ALS

NCT05104710

Amyotrophic Lateral Sclerosis

View study

RECRUITING

UPenn Observational Research Repository on Neurodegenerative Disease

NCT04715399

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 25, 2012Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Frontotemporal Degeneration(FTD)

Primary Progressive Aphasia(PPA)

+7 more

View study

RECRUITINGNA